

Journal of Visualized Experiments

A customizable protocol for string assembly gRNA cloning (STAgR)

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58556R1
Full Title:	A customizable protocol for string assembly gRNA cloning (STAgR)
Keywords:	CRISPR; Cas9; dCas9; gRNA cloning; gRNA multiplexing; genome editing; epigenome editing; transcriptome editing
Corresponding Author:	Stefan H. Stricker Ludwig-Maximilians-Universitat Munchen Planegg-Martinsried, Bavaria GERMANY
Corresponding Author's Institution:	Ludwig-Maximilians-Universitat Munchen
Corresponding Author E-Mail:	stefan.stricker@helmholtz-muenchen.de;stricker@biologie.uni-muenchen.de
Order of Authors:	Christopher Breunig Andrea Neuner Jessica Schwab Wolfgang Wurst Magdalena Götz Stefan H. Stricker
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	BioMedical Center, Grosshaderner Strasse 9, Planegg-Martinsried, 82152, Germany

TITLE:

A Customizable Protocol for String Assembly gRNA Cloning (STAgR)

AUTHORS & AFFILIATIONS:

Christopher T. Breunig^{1,2}, Andrea M. Neuner^{1,2}, Jessica Schwab³, Wolfgang Wurst³, Magdalena Götz^{2,4}, Stefan H. Stricker^{1,2}

¹MCN Junior Research Group, Munich Center for Neurosciences, Ludwig-Maximilian-Universität, BioMedical Center, Grosshaderner Strasse 9, Planegg-Martinsried, 82152, Germany

²Institute of Stem Cell Research, Helmholtz Zentrum, German Research Center for Environmental Health

³Institute of Developmental Genetics, Helmholtz Zentrum, German Research Center for Environmental Health

⁴Physiological Genomics, BioMedical Center, Ludwig-Maximilian-Universität, Planegg-Martinsried, Germany

Corresponding Author:

Stefan H. Stricker (stricker@bio.uni-muenchen.de)

Email Addresses of Co-Authors:

christopher.breunig@helmholtz-muenchen.de

andrea.neuner@tum.de

jessica.schwab@helmholtz-muenchen.de

wurst@helmholtz-muenchen.de

magdalena.goetz@helmholtz-muenchen.de

KEYWORDS:

CRISPR, Cas9, dCas9, gRNA cloning, gRNA multiplexing, genome editing, transcriptome editing

SHORT ABSTRACT:

Here, we present string assembly gRNA cloning (STAgR), a method to easily multiplex gRNA vectors for CRISPR/Cas9 approaches. STAgR makes gRNA multiplexing simple, efficient and customizable.

LONG ABSTRACT:

The bacterial CRISPR/Cas9 system has substantially increased methodological options for life scientists. Due to its utilization, genetic and genomic engineering became applicable to a large range of systems. Moreover, many transcriptional and epigenomic engineering approaches are now generally feasible for the first time. One reason for the broad applicability of CRISPR lies in its bipartite nature. Small gRNAs determine the genomic targets of the complex, variants of the protein Cas9, and the local molecular consequences. However, many CRISPR approaches depend on the simultaneous delivery of multiple gRNAs into individual cells. Here, we present a customizable protocol for string assembly gRNA cloning (STAgR), a method that allows the simple, fast and efficient generation of multiplexed gRNA expression vectors in a single cloning

step. STAgR is cost-effective, since (in this protocol) the individual targeting sequences are introduced by short overhang primers while the long DNA templates of the gRNA expression cassettes can be re-used multiple times. Moreover, STAgR allows single step incorporation of a large number of gRNAs, as well as combinations of different gRNA variants, vectors and promoters.

INTRODUCTION:

String assembly gRNA cloning (STAgR) is a method enabling efficient overnight generation of expression vectors containing multiple gRNA expression cassettes in one single cloning step. The STAgR protocol does not depend on specialist expertise or materials and offers multiple options for customization.

The bacterial CRISPR protein Cas9 has a unique capacity. It is able to find and selectively bind only those DNA sequences encoded in naturally occurring crRNAs or engineered gRNAs¹. Its utilization as a molecular tool has enabled a large number of approaches that were impossible, unfeasible or only limited to certain cellular models until recently. These include targeted gene mutations², genome engineering³, epigenome editing⁴⁻⁶, transcriptional activation and gene silencing^{7,8}. As far as we know CRISPR is universally deployable, as reports of its application exist for a wide range of target sites, cell types and species. However, many CRISPR applications depend directly or indirectly on the delivery of multiple gRNAs including a series of genomic manipulations (translocations^{9,10}, medium¹¹ and large scale genomic alterations^{12,13}), genome engineering (use of Cas9 nickases¹⁴, generation of conditional alleles^{11,15} or serial mutations¹⁶) and tracing strategies¹⁷. Moreover, for other approaches (transcriptional engineering¹⁸, epigenome engineering^{19,20}) multiple targeting sites are not strictly mandatory, however they reach their maximum effect often only under this condition.

Several useful methods have been described to generate gRNA vectors containing more than one gRNA expression cassette²¹⁻²⁷. Here, we present a protocol for STAgR, string assembly gRNA cloning, which is outstanding in its combination of simplicity and speed (only one overnight cloning step is needed), low cost (as DNA templates can be reused multiple times), customizability (for different gRNA systems and promoters) and effectiveness (it allows the generation of vectors containing high numbers of gRNA cassettes)²⁸.

STAgR can in principle be used to generate expression vectors with few (1–2 gRNAs), several (3–5 gRNAs) and some of the highest number of expression cassettes reported so far (6–8 gRNAs)²⁸. Similarly, STAgR is applicable for any gRNA sequence, backbone or promoter. Since however, STAgR is mainly based on polymerase chain reactions (PCR) and Gibson assembly, gRNAs with high sequence similarities should be generated using an alternative method.

PROTOCOL:

1. Design of STAgR Cloning Strategy

1.1. Decide on how many gRNA cassettes will be included in one expression vector and in which order. Determine which promoters and gRNA scaffolds should be used for each of the gRNAs. Design the gRNAs by using any online tool (e.g., www.benchling.com).

2. Design of STAgR Cloning Primers with Overhangs

Note: The sense protospacer sequence of the last gRNA and the antisense of the first gRNA respectively are added to the PCR primers used for amplification of the vector backbone (**Figure 1**). The remaining sequences are amplified from the strings, thereby attaching the sense and antisense gRNAs in the desired order. The first string piece is amplified with a forward primer containing the first gRNA N20 sequence as an overhang and a reverse primer with the second gRNA N20 sequence (reverse complement) as an overhang. All the following pieces are generated accordingly.

2.1. Add N20 gRNA sequences to the forward amplification primers for STAgR DNA string as overhangs (**Table 1**). Add sense gRNA sequences 5' to the forward primer "scf-FP" (for a conventional scaffold) or "sam-FP" (for a MS2 containing scaffold). FP primers anneal to the scaffold/MS2 part of the respective STAgR string (**Figure 1**).

2.2. Add the reverse complement N20 gRNA sequence to the reverse primer sequences. Choose RP primers depending on the specific promoters and strings used (hU6-RP, mU6-RP, 7sK-RP, H1-RP).

3. Generation of STAgR Cloning Fragments

3.1. To generate the individual cloning fragments for Gibson assembly, perform PCRs by setting up 10 µL of high fidelity (HF) buffer, 1 µL of 10 mM dNTPs, 0.25 µL of overhang-primer (100 µM), 10 ng of the DNA template (string or vector), 0.5 µL HF polymerase, 1.5 µL of dimethyl sulfoxide (DMSO) and add H₂O to make a final volume of 50 µL.

Note: Use the plasmid "STAgR_Neo" as a template for the backbone PCR to incorporate the gRNA scaffold to the last gRNA, if the SAM Scaffold is chosen, use "STAgR_SAM". For a STAgR plasmid with six gRNA cassettes for example, six PCRs are necessary, five with DNA strings as templates and one with the vector backbone as the template.

3.2. Incubate reactions on a thermocycler using the following conditions: 1 cycle of 98 °C for 1 min 30 s; 38 cycles of 98 °C for 10 s, 59 °C (for gRNA scaffold)/ 68 °C (for SAM loop) for 10 s, 72 °C for 30 s (for inserts) / 1 min 30 s (for vectors); 1 cycle of 72 °C for 10 min.

3.3. Remove 5.5 µL from the PCR reaction, add loading dye and analyze the amplified fragments on a 1% agarose gel. Load an appropriate DNA ladder for sizing (100 bp DNA ladder/1 kb DNA ladder) and run the gel in an appropriate gel running buffer (e.g., TLE buffer) at 120 V for 30 min.

3.4. While the gel is running, add 5 μL of the buffer provided with the restriction enzyme and 0.5 μL *DpnI* (10 units) to the remaining 44.5 μL PCR reaction and incubate for 30 min to 1 h at 37 °C.

3.5. Perform DNA purification using magnetic beads.

3.5.1. Add 1.8 μL magnetic beads per 1 μL of PCR product and mix by pipetting up and down. Incubate for 2 min at room temperature (RT).

3.5.2. Separate beads and DNA fragments from residual liquid with a magnet. Wash beads twice with 70% ethanol by rinsing the pellet without resuspending completely.

3.5.3. Remove all ethanol with a pipette and let the pellet air dry.

3.5.4. Dissolve the pellet in 15-20 μL H_2O by pipetting up and down and separate the beads from the liquid by using a magnet. Transfer the clear supernatant to a new tube.

Note: Alternatively, column-based reaction clean-up kits can be used.

3.6. Determine DNA concentrations using a spectrophotometer as described elsewhere²⁹.

4. Gibson Assembly Reaction and Bacterial Transformation

Note: The following steps are adapted from Gibson *et al.*³⁰.

4.1. Prepare a homemade Gibson reaction mix or use a commercial Gibson cloning kit.

4.1.1. Combine 3 mL of 1 M Tris (Tris(hydroxymethyl)aminomethane)-HCl at pH 7.5, 300 μL of 1 M MgCl_2 , 60 μL of 100 mM dGTP (deoxyguanosine triphosphate), 60 μL of 100 mM dATP (deoxyadenosine triphosphate), 60 μL of 100 mM dTTP (deoxythymidine triphosphate), 60 μL of 100 mM dCTP (deoxycytidine triphosphate), 300 μL of 1 M DTT (dithiothreitol), 1.5 g of PEG-8000 (polyethylene glycol), 300 μL of 100 mM NAD (nicotinamide adenine dinucleotide) and add H_2O to obtain 6 mL of 5 \times isothermal reaction buffer.

Note: Aliquoted buffer can be stored at -20 °C for at least 12 months.

4.1.2. For the Gibson assembly master mix, combine 320 μL of 5 \times isothermal reaction buffer with 697 μL of H_2O and add 3 μL of 10 U/ μL T5 exonuclease, 20 μL of 2 U/ μL DNA polymerase and 160 μL of 40 U/ μL *Taq* DNA ligase.

Note: This mix can be aliquoted and stored at -20 °C for at least 12 months.

4.2 Use 7.5 μL of assembly master mix with 2.5 μL of insert and vector. For a 2 \times STAgR reaction use a molar vector to insert ratio of 1:1 but not more than 0.2 pmol of DNA in total. For more

than 2 gRNA expression cassettes, use a vector to insert ratio of 1:3 but do not exceed a total DNA amount of 0.5 pmol.

Note: All amplified gRNA expression cassettes should be used in equimolar amounts. Include a plasmid control with the identical amount of vector but no inserts to control for undigested template vector (and/or self-ligation).

4.3. Incubate samples at 50 °C for 45 to 60 min. Store samples on ice or at -20 °C for subsequent transformation.

Note: The protocol can be paused here.

4.4. Directly transform half of the mix into chemically competent bacteria.

4.4.1 Thaw chemically competent TOP10 *E. coli* bacteria on ice.

4.4.2 Add 5 µL of the Gibson mix to 50 µL of competent bacteria. Gently mix by flicking the bottom of the tube. Incubate on ice for 30 min.

4.4.4 Perform a heat shock by placing the tube in a 42 °C water bath or a heat block for 45 s.

4.4.5 Put the tubes back on ice. Add 250 µL of SOC medium to the bacteria and let them recover at 37 °C in a shaking incubator for 30–45 min.

4.5. After recovery, plate the transformed bacteria onto 1.5% lysogeny broth (LB) agar plates containing ampicillin (100 µg/ mL) and incubate overnight at 37 °C.

5. Selecting STAgR Clones by Bacterial Colony PCR

5.1. Prepare at least two sets of 200 µL PCR reaction tubes (between 3 and 24) for each construct, which are labeled identically.

5.2. Fill one set with 100 µL LB medium containing 100 µg/ mL ampicillin.

5.3. Use a sterile pipette tip to scratch off the biological material of one bacterial colony and spread it at the bottom of the empty 100 µL PCR reaction tube. Immediately transfer the tip to the second corresponding reaction tube containing the LB medium.

5.4. Swirl the tip around gently to ensure some of the bacteria are transferred to the LB media and incubate at 37 °C for later use.

5.5. Set up a PCR master mix (10 µL per reaction).

5.5.1. For 10 reactions, combine 10 μ L *Taq* buffer, 2 μ L 10 mM dNTPs, 0.5 μ L of primer (100 μ M), 0.5 μ L of *Taq* polymerase and add H₂O to a volume of 100 μ L.

5.5.2. Use the following primers: StAgR_seq_fwd2: ACTGGATCCGGTACCAAGG, StAgR_seq_rev: TTACGGTTCCTGGCCTTTTG.

5.6. Add 10 μ L of the PCR master mix to the labeled PCR reaction tubes without the LB media.

5.7. Incubate reactions on a thermocycler using the following conditions: 1 cycle of 94 °C for 5 min, 38 cycles of 94 °C for 30 s, 55 °C for 30 s, 72 °C for 2 min; 1 cycle of 72 °C for 10 min.

Note: Elongation time (72 °C step) should be increased with the number of gRNA expression cassettes. Calculate theoretical size of inserts using **Table 2** and use 1 min per 1 kb at 72 °C.

5.8. Add loading dye and analyze the amplified fragments on a 1% agarose gel. Load an appropriate DNA ladder for sizing (1kb DNA Ladder) and run the in appropriate gel running buffer (e.g., TLE Buffer) at 120 V for 30 min.

5.9. Calculate the theoretical size of the amplicon with the help of **Table 2** by adding up the individual sizes of used promoters, gRNA scaffolds and number of N20 sequences. From the results of the colony PCR, identify the bacterial clones based on the correct band size and whether they are likely to harbor correct vectors.

5.10. Inoculate a 2.5 mL overnight LB culture (with 100 μ g/mL ampicillin) with the corresponding 100 μ L culture, set up earlier. Incubate at 37 °C for 12 h.

5.11. Extract plasmid DNA using a commercial plasmid mini kit and manufacturer's instructions³¹.

5.12. Sequence the plasmids using the following primers: StAgR_seq_fwd1 (GAGTTAGGGGCGGGACTATG), StAgR_seq_fwd2 (ACTGGATCCGGTACCAAGG) and StAgR_seq_rev (TTACGGTTCCTGGCCTTTTG) by Sanger Sequencing.

REPRESENTATIVE RESULTS:

Following the protocol at hand makes the generation of customized multiplexing gRNA vectors feasible (**Figure 1**). Representative results of STAgR approaches using six different gRNA cassettes are depicted in **Figure 2**. **Figure 2A** shows a typical outcome of the PCRs used to obtain the STAgR pieces (protocol 3.1–3.3). The six amplicons (BB, S1–S5) represent linear DNA pieces containing the individual gRNA N20 sequences on their ends. The plasmid backbone (BB) is now extended with the targeting sequences of gRNA1 and gRNA6 and therefore possesses the required overlaps to two other PCRs (S1 and S5) for Gibson assembly (**Figure 2A**, **Table 3**). After purification a DNA yield of at least 1 μ g for vectors and inserts can be achieved.

After Gibson assembly, bacterial transformation should result in 100 to 700 bacterial colonies. **Figure 2B** shows a representative analysis of 10 bacterial colonies via colony PCR, following a

STAgR protocol with six gRNA cassettes. Gel electrophoresis indicates that three clones show the expected amplicon size for full assembly (Table 2). Other clones likely received STAgR vectors containing one to five gRNA cassettes, whereas one clone (Figure 2B, No.18) is empty.

FIGURE AND TABLE LEGENDS:

Figure 1: Overview of STAgR primer design. First gRNA number and scaffolds are chosen, then gRNA order and promoter and last, which type of vector should be used. For each gRNA, a specific forward primer with the gRNA targeting sequence in sense orientation and either the common part of “scf-FP” or “sam-FP” is designed. Similarly, to generate the individual reverse primer the corresponding promoter sequence (RP) is fused with the reverse complement of the N20 sequence of the next gRNA.

Figure 2: Representative results of STAgR approaches using six different gRNA cassettes. (A) Representative example of a PCR of five inserts as well as the vector STAgR_Tomato. (B) Colony PCR of a 6× STAgR reaction using hU6 and mU6 promoters and canonical gRNA as well as SAM scaffolds. 10 bacterial colonies were analyzed, of which 3 showed the expected band indicating complete assembly. Ladder: 1kb plus, numbers in base pairs (bp).

Table 1: Primer sequences for gRNA scaffolds and promoters.

Table 2: Theoretical sizes of each expression cassette to calculate colony PCR outcome.

Table 3: Sizes of promoters and scaffolds.

Table 4: Calculated sizes of STAgR pieces after PCR.

DISCUSSION:

Here we present a detailed protocol for STAgR allowing the fast and simple generation of gRNA expression plasmids of varying sizes. This protocol can be used for one-step generation of gRNA plasmids with 2–8 gRNA expression cassettes (with or without two MS2 RNA aptamers) into the gRNA expression vector STAgR_Neo, and the use of human U6, mouse U6, human 7sK and human H1 promoters^{28,32,33}. If more than four cassettes are desired, it is recommended to use at least two different promoter/scaffold types to increase efficiency. Other vectors, promoters and promoter combinations as well as more than 8 gRNA cassettes might be feasible as well; however, this has not been tested. Although in our experience the method works reliably and reproducibly, we have determined critical steps and troubleshooting strategies should the expected outcome not immediately occur. In our experience some steps are pivotal for the success of the approach: first and foremost, it is important to use the correct molar ratios of inserts to the vector backbone at the Gibson assembly step (3:1). However, we noticed that for some gRNA sets a 1:1 ratio of inserts to vector is beneficial, even when the gRNA cassette number does exceed two. Secondly, the period of the Gibson assembly reaction should be sufficiently long (at least 45 min recommended).

STAgR can be employed with a large number of modifications. Targeting sequences, gRNA numbers and scaffolds, promoters and vector backbones can be customized and freely combined. However, each combination may have slightly different requirements. In our experience, if medium or high numbers of gRNA cassettes (>4) are desired but not obtained immediately, usually the fastest way to overcome this issue is to change the order of the individual gRNA cassettes in the vector. Similarly, combining different gRNA promoters and scaffolds improves efficiency (and thus lowers the required number of colony PCRs that have to be scored) when many gRNA cassettes are cloned. We found that incorrect clones are usually generated by the spontaneous conjunction of repeated sequences during Gibson assembly. Although this can reduce the efficiency of the method, this also results in the simultaneous generation of vectors with functional gRNA subsets²⁸.

Generation of multiplexing gRNA vectors containing more than one gRNA expression cassette has been reported with a number of different methods²¹⁻²⁷. While some employ simultaneous or sequential cloning of gRNA pairs^{22,34}, others depend on Golden Gate assembly and several sequential cloning steps^{25,35}. A special approach has been used by *Xie et al.*, by employing the endogenous cellular tRNA processing system to cut several gRNAs out of a single progenitor transcript³⁶. The advantage of this method is the requirement of only one promoter; the drawback is the need of newly synthesized DNA fragments for each gRNA combination. Each gRNA multiplexing method has advantages and disadvantages; STAgR combines simplicity with efficiency, high number of possible gRNA cassettes with low cost.

STAgR (and other multiplexing systems) will likely be instrumental in enabling efficient (and simultaneous) disruption of multiple genes *in vivo*, as pioneered in zebrafish brains²⁸. Another future application of gRNA multiplexing vectors is the promise for manipulation of complete transcriptional programs in contrast to the induction or repression of single genes. Likely, these approaches will allow transforming cells and organs at will to a much higher degree than it is possible today.

ACKNOWLEDGMENTS:

The authors would like to thank Prof. Dr. Stephan Beck and Prof. Dr. Jovica Ninkovic for their input, help and support in developing the STAgR method. Tobias Klötzer, Anna Köferle and Valentin Baumann for helpful comments. The work has been supported by DFG (STR 1385/1-1).

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

- 1 Barrangou, R. Diversity of CRISPR-Cas immune systems and molecular machines. *Genome Biol.* **16** 247, doi:10.1186/s13059-015-0816-9, (2015).
- 2 Jinek, M. *et al.* A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. **337** (6096), 816-821, doi:10.1126/science.1225829, (2012).
- 3 Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science*. **339** (6121), 819-823, doi:10.1126/science.1231143, (2013).

349 4 Pulecio, J., Verma, N., Mejia-Ramirez, E., Huangfu, D. & Raya, A. CRISPR/Cas9-Based
350 Engineering of the Epigenome. *Cell Stem Cell*. **21** (4), 431-447, doi:10.1016/j.stem.2017.09.006,
351 (2017).

352 5 Köferle, A., Stricker, S. H. & Beck, S. Brave new epigenomes: the dawn of epigenetic
353 engineering. *Genome Med*. **7** (1), 59, doi:10.1186/s13073-015-0185-8, (2015).

354 6 Stricker, S. H., Koferle, A. & Beck, S. From profiles to function in epigenomics. *Nature*
355 *Reviews Genetics*. **18** (1), 51-66, doi:10.1038/nrg.2016.138, (2017).

356 7 Gilbert, L. A. *et al.* CRISPR-mediated modular RNA-guided regulation of transcription in
357 eukaryotes. *Cell*. **154** (2), 442-451, doi:10.1016/j.cell.2013.06.044, (2013).

358 8 Maeder, M. L. *et al.* CRISPR RNA-guided activation of endogenous human genes. *Nature*
359 *Methods*. **10** (10), 977-979, doi:10.1038/nmeth.2598, (2013).

360 9 Lekontsev, S., Aligianni, S., Lapao, A. & Burckstummer, T. Efficient generation and
361 reversion of chromosomal translocations using CRISPR/Cas technology. *BMC Genomics*. **17** (1),
362 739, doi:10.1186/s12864-016-3084-5, (2016).

363 10 Jiang, J. *et al.* Induction of site-specific chromosomal translocations in embryonic stem
364 cells by CRISPR/Cas9. *Scientific Reports*. **6** 21918, doi:10.1038/srep21918, (2016).

365 11 Yang, H. *et al.* One-step generation of mice carrying reporter and conditional alleles by
366 CRISPR/Cas-mediated genome engineering. *Cell*. **154** (6), 1370-1379,
367 doi:10.1016/j.cell.2013.08.022, (2013).

368 12 Wang, L. *et al.* Large genomic fragment deletion and functional gene cassette knock-in *via*
369 Cas9 protein mediated genome editing in one-cell rodent embryos. *Scientific Reports*. **5** 17517,
370 doi:10.1038/srep17517, (2015).

371 13 Zhang, L. *et al.* Large genomic fragment deletions and insertions in mouse using
372 CRISPR/Cas9. *PLoS ONE*. **10** (3), e0120396, doi:10.1371/journal.pone.0120396, (2015).

373 14 Shen, B. *et al.* Efficient genome modification by CRISPR-Cas9 nickase with minimal off-
374 target effects. *Nature Methods*. **11** (4), 399-402, doi:10.1038/nmeth.2857, (2014).

375 15 Yang, H., Wang, H. & Jaenisch, R. Generating genetically modified mice using CRISPR/Cas-
376 mediated genome engineering. *Nature Protocols*. **9** (8), 1956-1968, doi:10.1038/nprot.2014.134,
377 (2014).

378 16 Wang, H. *et al.* One-step generation of mice carrying mutations in multiple genes by
379 CRISPR/Cas-mediated genome engineering. *Cell*. **153** (4), 910-918,
380 doi:10.1016/j.cell.2013.04.025, (2013).

381 17 Kalhor, R., Mali, P. & Church, G. M. Rapidly evolving homing CRISPR barcodes. *Nature*
382 *Methods*. **14** (2), 195-200, doi:10.1038/nmeth.4108, (2017).

383 18 Chavez, A. *et al.* Highly efficient Cas9-mediated transcriptional programming. *Nature*
384 *Methods*. **12** (4), 326-328, doi:10.1038/nmeth.3312, (2015).

385 19 Bultmann, S. & Stricker, S. H. Entering the post-epigenomic age: back to epigenetics. *Open*
386 *Biology*. **8** (3), doi:10.1098/rsob.180013, (2018).


387 20 Vora, S., Tuttle, M., Cheng, J. & Church, G. Next stop for the CRISPR revolution: RNA
388 guided epigenetic regulators. *FEBS Journal*. doi:10.1111/febs.13768, (2016).

389 21 Maddalo, D. *et al.* In vivo engineering of oncogenic chromosomal rearrangements with
390 the CRISPR/Cas9 system. *Nature*. **516** (7531), 423-427, doi:10.1038/nature13902, (2014).


391 22 Nageswaran, S. *et al.* CRISPR Guide RNA Cloning for Mammalian Systems. *Journal of*
392 *Visualized Experiments*. (in Press).

- 23 Wrighton, K. H. Synthetic biology: Multiplex genome engineering in eukaryotes. *Nature Reviews Genetics*. **19** (1), 6-7, doi:10.1038/nrg.2017.103, (2018).
- 24 Yan, Q. *et al.* Multiplex CRISPR/Cas9-based genome engineering enhanced by Drosha-mediated sgRNA-shRNA structure. *Scientific Reports*. **6** 38970, doi:10.1038/srep38970, (2016).
- 25 Kabadi, A. M., Ousterout, D. G., Hilton, I. B. & Gersbach, C. A. Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. *Nucleic Acids Research*. **42** (19), e147, doi:10.1093/nar/gku749, (2014).
- 26 Cress, B. F. *et al.* CRISPathBrick: Modular Combinatorial Assembly of Type II-A CRISPR Arrays for dCas9-Mediated Multiplex Transcriptional Repression in *E. coli*. *ACS Synthetic Biology*. **4** (9), 987-1000, doi:10.1021/acssynbio.5b00012, (2015).
- 27 Port, F. & Bullock, S. L. Augmenting CRISPR applications in *Drosophila* with tRNA-flanked sgRNAs. *Nature Methods*. **13** (10), 852-854, doi:10.1038/nmeth.3972, (2016).
- 28 Breunig, C. T. *et al.* One step generation of customizable gRNA vectors for multiplex CRISPR approaches through string assembly gRNA cloning (STAgR). *PLoS ONE*. **13** (4), e0196015, doi:10.1371/journal.pone.0196015, (2018).
- 29 Barbas, C. F., 3rd, Burton, D. R., Scott, J. K. & Silverman, G. J. Quantitation of DNA and RNA. *CSH Protoc.* **2007** pdb ip47, doi:10.1101/pdb.ip47, (2007).
- 30 Gibson, D. G. Enzymatic assembly of overlapping DNA fragments. *Methods Enzymology*. **498** 349-361, doi:10.1016/B978-0-12-385120-8.00015-2, (2011).
- 31 Maniatis, T., Fritsch, E. F. & Sambrook, J. *Molecular cloning : a laboratory manual*. (Cold Spring Harbor Laboratory, 1982).
- 32 Koferle, A. *et al.* CORALINA: a universal method for the generation of gRNA libraries for CRISPR-based screening. *BMC Genomics*. **17** (1), 917, doi:10.1186/s12864-016-3268-z, (2016).
- 33 Koferle, A. & Stricker, S. H. A Universal Protocol for Large-scale gRNA Library Production from any DNA Source. (130), e56264, doi:doi:10.3791/56264, (2017).
- 34 Vidigal, J. A. & Ventura, A. Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries. *Nature Communications*. **6** 8083, doi:10.1038/ncomms9083, (2015).
- 35 Sakuma, T., Nishikawa, A., Kume, S., Chayama, K. & Yamamoto, T. Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. *Scientific Reports*. **4** 5400, doi:10.1038/srep05400, (2014).
- 36 Xie, K., Minkenberg, B. & Yang, Y. Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system. *Proceedings of the National Academy of Sciences of the United States of America*. **112** (11), 3570-3575, doi:10.1073/pnas.1420294112, (2015).


1. Number and Sequence 2. Order and Scaffold 3. Promoter 4. Vector and Backbone



A. String and vector PCR



B. Colony PCR



Forward primer for String and Vector
scaffold_fwd
SAM_fwd
Reverse primer for String and Vector
hU6_rev
mU6_rev
hH1_rev
h7SK_rev

GTTTTAGAGCTAGAAATAGCAAGTT
GTTTTAGAGCTAGGCCAACATGAGG

CGGTGTTTCGTCCTTT
CAAACAAGGCTTTTCTCCAAGG
CTGGGAAAGAGTGGTCTCATACAGA
CCGAGGTACCCAAGCGG

Sizes of promoters and scaffolds.
hU6
hH1
mU6
h7SK
gRNA scaffold
SAMloop + gRNA scaffold

265bp

225bp

316bp

245bp

83bp

143bp

	hU6	hH1	mU6
gRNA Scf	400bp	360bp	451bp
SAM	460bp	420bp	511bp

h7SK	STAgR_N eo	STAgR_td Tomato
380bp	3722bp	4487bp
440bp	-	-

	hU6	hH1	mU6	h7SK
gRNA Scf	368bp	328bp	419bp	348bp
SAM	428bp	388bp	479bp	408bp

STAgR_Neo	STAgR_tdTomato
+74bp	+67bp

Name of Material/ Equipment	Company	Catalog Number
Phusion High- Fidelity DNA Polymerase	NEB	M0530L
dNTPs	Life Technology	R0191
dATP	Life Technology	R0141
dCTP	Life Technology	R0151
dGTP	Life Technology	R0161
dTTP	Life Technology	R0171
Agarose	VWR	443666A
DpnI	NEB	R0176S
AMPure XP Beads	Beckman Coulter	A63881
Tris HCL	Roth	9090.2
DTT	Life Technology	R0861
PEG 8000	VWR	RC- 077
NAD	Cayman Chemicals Company	16077
T5 Exonuclease	NEB	M0363S
Taq DNA Ligase	NEB	M0208S
Ampicilin	SigmaAldrich	PHR1393-1G
DNA Ladder 1kb Plus	Thermo Scientific	SM0311
Plasmid Mini Kit	Thermo Scientific	K0503
Plasmid and Primer Sequences		
EDTA	PanReacAppliChem	6381-92-6
MgCl ₂	SigmaAldrich	M8266
Top10 chemically competent bacteria	Thermo Scientific	C404003
S.O.C. Medium	Thermo Scientific	15544034
Yeast- Extract	SigmaAldrich	Y1625
NaCl	SigmaAldrich	S7653
Peptone	SigmaAldrich	91249
Agar-Agar	SigmaAldrich	5040
Taq DNA Polymerase	Quiagen	201203

Comments/Description

Polymerase for Gibson Master Mix as well as all PCRs

dNTPs for all PCRs

dNTPs for Gibson Master Mix

dNTPs for Gibson Master Mix

dNTPs for Gibson Master Mix

dNTPs for Gibson Master Mix

for DNA clean up

for Gibson Master Mix

for Gibson Master Mix

for Gibson Master Mix

for Gibson Master Mix

for Gibson Master Mix

for Gibson Master Mix

All sequences available at Figshare (<https://goo.gl/UGdc3Q>).

for TLE Buffer

for Gibson Master Mix

for lysogenic broth (LB Media)

for lysogenic broth (LB Media)

for lysogenic broth (LB Media)

for lysogenic broth (LB Media)



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: A customizable protocol for string assembly gRNA cloning
Author(s): Brenning, Wenner, Schwab, Wurst, Götz, Stricker

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☐ Standard Access ☒ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in Section 3 above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. Transfer, Governing Law. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name: Dr. Stefan H. Stricker
Department: Munich Center for Neuroscience
Institution: BioMedical Center
Article Title: A customizable protocol for string assembly gRNA cloning
Signature: [Signature] Date: 1.6.18

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051



LUDWIG-
MAXIMILIANS-
UNIVERSITÄT
MÜNCHEN

BIOZENTRUM DER LMU
DEPARTMENT BIOLOGIE II



MCN Junior Research Group · Großhaderner Str. 9 · D-82152 Planegg-Martinsried

Alisha DSouza, Ph.D.

JoVE,

1 Alewife Center, Suite 200

Cambridge, MA 02140, US

Dr. Stefan H. Stricker,
MCN Junior Research Group,
Munich Center for Neurosciences

Telefon +49 (0)89 2180-74
Telefax +49 (0)89 2180-74
stefan.stricker@biologie.uni-
muenchen.de

Grosshaderner Strasse 9,
Planegg-Martinsried,
D-82152 Planegg-Martinsried

JoVE58556

Martinsried, 17.07.2018

Dear Dr. DSouza,

We have revised our manuscript "A customizable protocol for string assembly gRNA cloning (STAgR)" (JoVE58556) and I enclose an updated version of the manuscript (marked and unmarked). We are encouraged that both reviewers have recognized the value of the presented protocol for the scientific community.

We are confident that we have addressed all the points raised by the reviewers and are grateful for their suggestions. We have altered Figure 1 with the aim to make the protocol procedure easier to understand. We also would suggest using a similar (animated) figure in the video.

In addition, we have adopted the suggested editorial changes, tried to improve the readability of our manuscript and thus hope that it is now acceptable for publication in JoVE.

Many thanks for considering our work,

Yours sincerely,

Dr. Stefan H. Stricker